晚期复发子宫内膜癌患者的特征
İlker Çakır1, Varol Gülseren2, İsa Aykut Özdemir3
1Department of Obstetrics and Gynecology, Tepecik Education and Research Hospital, İzmir, Turkey.
Journal of cancer research and therapeutics
|March 30, 2024
概括
这项研究检查了晚期转移的子宫内膜癌患者. 子宫内膜类型子宫内膜癌患者的预后更好,手术切除可能会改善晚期复发的生存率.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症研究 癌症研究
- 临床医学 临床医学
背景情况:
- 在子宫内膜癌 (EC) 的晚期转移带来了独特的挑战.
- 了解复发模式和生存率对于患者管理至关重要.
研究的目的:
- 评估经历晚期转移的子宫内膜癌患者的结果.
- 分析复发位置对生存的影响.
主要方法:
- 在1996-2018年间诊断和治疗的EC患者的回顾性审查.
- 晚期复发的定义是发生在初级治疗后三年后.
- 对复发后生存率 (PRS) 和无病生存率 (DFS) 的分析.
主要成果:
- 42名患者有晚期转移:20名本地区域和22名外骨盆.
- 在局域性 (61个月) 和外骨盆性 (65个月) 复发中,DFS的中位数与局域性 (61个月) 和外骨盆性 (65个月) 复发类似.
- 五年PRS率为61.1%,在复发类型之间没有显著差异.
结论:
- 子宫内膜类型EC与晚期转移病例的更好的预后有关.
- 复发位置 (局部区域与外骨盆) 并没有显著影响存活率.
- 手术切除可能会提高患有局部区域晚期转移的患者的生存率.
更多相关视频
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Disorders of the Female Reproductive System
357
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
357
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345


